Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
This acquisition enables MTD to open new, strategic markets
The company had earlier announced about the approval received from the MHRA for Liraglutide
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Both organisations enter into a long- term collaboration to expand patient access in India
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Subscribe To Our Newsletter & Stay Updated
